Top Ten most popular articles on Pharmafile.com this week!
pharmafile | April 26, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK access innovative cancer drugs, this week. The institute suggested a new approach to funding models was necessary in order to encourage innovation.
The call came as Pfizer’s head of immune-oncology joined cancer focused firm Aduro Biotech as the company’s new CMO. The move may lead to new and innovative immunotherapies. Meanwhile GSK exec Richard Saynor was named as Novartis subsidiary Sandoz’ new CEO.
In other news, J&J settled a surgical mesh case for $9.9 million as the company faces litigation over not only the mesh but asbestos contaminated baby powder and opioids too. Check out this weeks’ top ten on Pharmafile.com!
The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK.
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, just three months after the firm laid of more than a third of its workforce, as it refocused its efforts on developing treatments for cancer.
Drugs for heart disease and angina have shown promise as preventative treatments for stroke and dementia, according to scientists from the University of Edinburgh.
China’s National Health Commission (NHC) has said it will monitor the country’s drugs market more closely in order to ensure a sufficient supply of essential medicines.
US firm Eli Lilly has agreed to sell the Chinese rights to two of its antibiotics, Ceclor (cefaclor) and Vancocin (vancomycin), to Chinese firm Eddingpharm in a deal worth $375 million.
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma in the treatment of spinal muscular atrophy (SMA) Type 1 in patients under six months old.
Healthcare conglomerate Johnson & Johnson has agreed to pay $9.9 million to settle a Washington state lawsuit over the firm’s alleged misrepresentation of the risks of pelvic mesh implants.
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor would be stepping up to lead Sandoz, its biosimilars and generics division, as CEO from no later than 1 August.
Novo Nordisk’s VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how having diabetes himself has shaped his outlook on treatment throughout his career.
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …
GSK and Save the Children have announced that they will be renewing their partnership for …